Neurocrine, Ciba-Geigy Ltd. deal

NBIX will receive a $3 million milestone payment from partner Ciba-Geigy for the initiation of a Phase I trial with NBI-5788, a peptide vaccine to treat multiple sclerosis. The trial will take place i...